ARS Pharmaceuticals Q1 Earnings Call Highlights

Lowenthal said ARS is focused connected 3 priorities for neffy: access, affordability and adoption. He noted that epinephrine is simply a mature, refill-driven market, with astir fractional of prescriptions typically coming from renewals that whitethorn beryllium written electronically without an bureau visit. As a newer entrant, neffy has relied much heavy connected caller in-office prescriptions, but Lowenthal said improved payer access, reduced prescribing friction and the maturation of refill cycles should enactment much scalable maturation implicit time.

Access Efforts Center connected Prior Authorization

Lowenthal said ARS ended the archetypal 4th with astir 90% commercialized sum for neffy, with 57% of covered lives having entree without anterior authorization. He said the institution views anterior authorization requirements and misperceptions astir out-of-pocket costs arsenic cardinal barriers to prescriber adoption.

→ Micron Investors Face a High-Stakes Moment After the Latest Rally

The institution is awaiting a imaginable formulary determination from CVS Health, which Lowenthal said includes Caremark, Aetna and Anthem. ARS submitted an updated connection successful precocious April seeking to adhd neffy to commercialized formularies without a anterior authorization requirement, targeting a July 1 effectual date. Lowenthal said the connection is successful the last stages of the formulary support process and that the institution expects to supply a much definitive update successful the coming weeks.

Chief Commercial Officer Eric Karas said during the question-and-answer league that CVS represents astir 15% of covered lives, Anthem astir 5% and Aetna astir 4%. He said ARS feels assured based connected its conversations with CVS Caremark and that a July 1 commencement would align with the company’s back-to-school selling and field-force plans.